Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00304694|
Recruitment Status : Unknown
Verified March 2006 by National Taiwan University Hospital.
Recruitment status was: Recruiting
First Posted : March 20, 2006
Last Update Posted : March 20, 2006
18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conventional approaches.
We propose to conduct a prospective study to evaluate therapeutic response using 18F-FDG PET before and after induction chemotherapy for locally advanced NPC patients.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Whole-Body 18F-FDG PET in Evaluating Induction Chemotherapeutic Response for Locally Advanced Nasopharyngeal Cancer Patients and Correlating With Histopathology: a Prospective Study|
|Study Start Date :||March 2006|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00304694
|Contact: Ruoh-Fang Yen, MD, PhD||886-2-23123456 ext email@example.com|
|National Taiwan University Hospital||Recruiting|
|Taipei, Taiwan, 10012|
|Principal Investigator: Ruoh-Fang Yen, MD, PhD|
|Principal Investigator:||Ruoh-Fang Yen, MD, PhD||National Taiwan University Hospital|